Browse > Article

Efficacy of Enrofloxacin and Silver Sulfadiaznine Topical Otic Suspension for the Treatment of Canine Otitis Externa  

Bae, Seulgi (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Kyungpook National University)
Kim, Byeongmok (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Kyungpook National University)
Choi, Sungwon (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Kyungpook National University)
Sin, Hui-Ju (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Kyungpook National University)
Lee, Young-Ju (Department of Veterinary Public Health, College of Veterinary Medicine, Kyungpook National University)
Oh, Tae-Ho (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Kyungpook National University)
Publication Information
Journal of Veterinary Clinics / v.30, no.3, 2013 , pp. 172-177 More about this Journal
Abstract
The aim of this study was to evaluate the in vivo and in vitro efficacy of enrofloxacin-silver sulfadiazine (Baytril$^{(R)}$ otic, Bayer, USA) for the treatment of otitis externa in dogs. Twenty-four dogs with otitis externa were included in this double-blinded, randomized study. The experimental group was treated with the Baytril$^{(R)}$ otic and the distilled water was applied to the control group. Both groups were administered each solution twice daily for 7 days and next 7 days off treatment. On days 0, 7 and 14, clinical signs, bacteriological and fungal counts were graded using semi-quantitative scales, respectively. For the evaluation of in vitro efficacy of Baytril$^{(R)}$ otic, we also performed Minimal Inhibitory Concentration (MIC) test by agar dilution method against Staphylococcus pseudintermedius, Pseudomonas aeruginosa and Malassezia pachydermatis. In the experimental group, the sum of clinical scores was decreased 81.0% and microbial scores were significantly reduced 87.0% at days 14, compared with day 0. The results of MIC testing were showed the concentration of enrofloxacin and silver sulfadiazine in Baytril$^{(R)}$ otic is high enough to kill for 3 infectious agents. No adverse reactions were observed in any of the dogs during this study. These results suggest that Baytril$^{(R)}$ otic are efficient and safe treatment for canine otitis externa.
Keywords
Otitis externa; dog; enrofloxacin; Baytril$^{(R)}$ otic;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Ginel PJ, Lucena R, Rodriguez JC, Ortega J. A semiquantitative cytological evaluation of normal and pathological samples from the external ear canal of dogs and cats. Vet Dermatol. 2002; 13: 151-156.   DOI   ScienceOn
2 Harvey RG, Delauche AJ, Harari J. Ear diseases of the dog & cat. London: Manson Publishing; 2005:
3 Hill PB, Lo A, Eden C, Huntley S, Morey V, Ramsey S, Richardson C, Smith DJ, Sutton C, Taylor MD, Thorpe E, Tidmarsh R, William. Survey of the prevalence, diagnosis and treatment of dermatological conditions in small animals in general practice. Vet Rec 2006; 158: 533-539.   DOI   ScienceOn
4 Huang H, Little CJL, McNeil PE. Histological changes in the external ear canal of dogs with otitis externa. Vet Dermatol 2009; 20: 422-428.   DOI   ScienceOn
5 Keskin O, Tel O, Kaya NA. Aerobic bacteria and fungi isolated from external ear canal of healthy dogs and the antibiotic susceptibility of staphylococci. J Anim Vet Adv 2010; 9: 496-500.   DOI
6 Lyskova P, Vydrzalova M, Mazurova J. Identification and antimicrobial susceptibility of bacteria and yeasts isolated from healthy dogs and dogs with otitis externa. J Vet Med A Physiol Pathol Clin Med 2007; 54: 559-563.   DOI   ScienceOn
7 Martín Barrasa JL, Lupiola Gómez P, González Lama Z, Tejedor Junco MT. Antibacterial susceptibility patterns of pseudomonas strains isolated from chronic canine otitis externa. J Vet Med B Infect Dis Vet Public Health 2000; 47: 191-196.   DOI   ScienceOn
8 Metry CA, Maddox CW, Dirikolu L, Johnson YJ, Campbell KL. Determination of enrofloxacin stability and in vitro efficacy against staphylococcus pseudintermedius and pseudomonas aeruginosa in four ear cleaner solutions over a 28 day period. Vet Dermatol 2012; 23: 23-28.   DOI   ScienceOn
9 Morris DO. Medical therapy of otitis externa and otitis media. Vet Clin North Am Small Anim Pract 2004; 34: 541-555.   DOI   ScienceOn
10 Oliveira LC, Leite CA, Brilhante RS, Carvalho CB. Comparative study of the microbial profile from bilateral canine otitis externa. Can Vet J 2008; 49: 785-788.
11 Trott D, Moss S, See A, Rees R. Evaluation of disc diffusion and MIC testing for determining susceptibility of pseudomonas aeruginosa isolates to topical enrofloxacin/silver sulfadiazine. Aust Vet J 2007; 85: 464-466.   DOI   ScienceOn
12 Saridomichelakis MN, Farmaki R, Leontides LS, Koutinas AF. Aetiology of canine otitis externa: A retrospective study of 100 cases. Vet Dermatol 2007; 18: 341-347.   DOI   ScienceOn
13 Schmidt A. In vitro activity of climbazole, clotrimazole and silver-sulphadiazine against isolates of malassezia pachydermatis. Zentralbl Veterinamed B 1997; 44 :193-197.
14 Tater KC, Scott D, Miller W, Erb H. The cytology of the external ear canal in the normal dog and cat. J Vet Med A 2003; 50: 370-374.   DOI   ScienceOn
15 Turkyilmaz S. Antibiotic susceptibility patterns of pseudomonas aeruginosa strains isolated from dogs with otitis externa. Turk J Vet Anim Sci 2008; 32: 37-42.
16 Zur G, Lifshitz B, Bdolah-Abram T. The association between the signalment, common causes of canine otitis externa and pathogens. J Small Anim Pract 2011; 52: 254-258.   DOI   ScienceOn
17 Anjum F, Mir A. Susceptibility pattern of pseudomonas aeruginosa against various antibiotics. Afr J Microbiol Res 2010; 4: 1005-1012.
18 Campbell JJ, Coyner KS, Rankin SC, Lewis TP, Schick AE, Shumaker AK. Evaluation of fungal flora in normal and diseased canine ears. Vet Dermatol 2010; 21: 619-625.   DOI   ScienceOn
19 Cole LK. Anatomy and physiology of the canine ear. Vet Dermatol 2010; 21: 221-231.   DOI   ScienceOn
20 Ettinger SJ, Feldman EC. Textbook of veterinary internal medicine: Diseases of the dog and the cat. St. Louis, Mo: Elsevier Saunders; 2010.
21 Freedom of information summary original new animal drug application NADA 141-176 Baytril Otic 2006.